Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/000331977202300907 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Mucosal Protection in the Treatment of Erosive Reflux Esophagitis: Mechanisms for Restoring Epithelial Permeability. A Randomized Clinical Trial.
J Gastrointestin Liver Dis
December 2024
Omsk State Medical University, Omsk, Russia.
Background And Aims: Gastroesophageal reflux disease (GERD) is widespread in the population and is characterized by the risk of developing Barrett's esophagus and associated adenocarcinoma. Key factors in the progression of the disease are not only the frequency and duration of reflux episodes, but also the resistance of the esophageal mucosa to aggressive reflux molecules. Assessment of the state of tight junction proteins, the rate of their recovery under the influence of various treatment regimens is an urgent task for choosing optimal approaches to curing patients with GERD.
View Article and Find Full Text PDFInvestigation of the effects of a new transdermal formulation of systemic diclofenac on the upper gastrointestinal mucosa in patients with low back pain: A comparative study with oral diclofenac.
J Gastroenterol Hepatol
December 2024
Hisamitsu Pharmaceutical Co., Inc., Tokyo, Japan.
Article Synopsis
- - This study examines the gastrointestinal safety of diclofenac sodium when administered via a transdermal patch (DSSP) versus an oral tablet (DST) in patients with low back pain (LBP).
- - Results showed that DSSP significantly reduced the incidence of gastroduodenal ulcers and erosions (26.7%) compared to DST (86.2%), demonstrating a -59.5% difference in risk.
- - Additionally, no adverse events were reported with DSSP, while 20% of patients using DST experienced mild adverse effects, highlighting DSSP's safety advantage.
Network Meta-Analysis of Comparing Different Dosages of Potassium-Competitive Acid Blocker With Proton-Pump Inhibitor in Acid-Related Disorders.
Clin Transl Gastroenterol
November 2024
Department of Elderly Digestive, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China .
Article Synopsis
- Potassium-competitive acid blockers (P-CABs) are being studied as potential treatments for acid-related disorders, with this analysis comparing their dosages to proton pump inhibitors (PPIs) for effectiveness and safety.
- The research included 12 studies and found that the 30mg dose of keverprazan (K30) was most effective for healing gastric/duodenal ulcers, while lowering adverse events was notably challenging for lansoprazole at 30mg (L30).
- For erosive esophagitis, 40mg of vonoprazan (V40) and 50mg of tegoprazan (T50) showed the best healing rates, but also presented varying risks of side effects
NSAID-induced Gastric Ulcer Disease: A Deleterious Connection.
Discov Med
September 2024
Department of Internal Medicine, Fazaia Ruth Pfau Medical College, 74350 Karachi, Pakistan.
Article Synopsis
- Gastric ulcers caused by long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) are a rising public health concern, primarily linked to their role in developing peptic ulcers.
- The review highlights various risk factors associated with NSAID use, including anticoagulant therapy, and discusses the clinical signs, symptoms, diagnosis, prevention, and treatment of these ulcers.
- Recommendations for prevention include using selective COX-2 inhibitors instead of traditional NSAIDs and minimizing dosages for patients with other health conditions to reduce ulcer risk.
Vonoprazan vs. Proton Pump Inhibitors for Treatment and Prevention of Gastric and/or Duodenal Ulcers: A Systematic Review with Meta-Analysis.
Dig Dis Sci
October 2024
Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Introduction: Although Vonoprazan, a potassium-competitive acid blocker, is superior to proton pump inhibitors (PPIs) in treating Helicobacter pylori and erosive esophagitis, its efficacy for treating gastric and/or duodenal ulcers remains controversial. This meta-analysis summarizes the efficacy and safety of Vonoprazan vs. PPI for treating and preventing gastric and/or duodenal ulcers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!